DiaMedica Therapeutics Inc. Net Income
DiaMedica Therapeutics Inc. (DMAC) reported Net Income of -$10.14 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement
us-gaap:NetIncomeLoss · last filed 2026-08-10
- DiaMedica Therapeutics Inc. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$10.14M.
- DiaMedica Therapeutics Inc. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$10.04M.
- DiaMedica Therapeutics Inc. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$8.74M.
- DiaMedica Therapeutics Inc. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$8.62M.
- DiaMedica Therapeutics Inc. net income (loss) attributable to parent for fiscal 2025 was -$32.77M.
- DiaMedica Therapeutics Inc. net income (loss) attributable to parent for fiscal 2024 was -$24.44M.
- DiaMedica Therapeutics Inc. net income (loss) attributable to parent for fiscal 2023 was -$19.38M.
- DiaMedica Therapeutics Inc. net income (loss) attributable to parent for fiscal 2022 was -$13.68M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$10.14M 10-Q · filed 2026-08-10 | -$20.18M 10-Q · filed 2026-08-10 | -$28.92M derived: sum of 3 quarters · filed 2026-08-10 | -$37.54M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$10.04M 10-Q · filed 2026-08-10 | -$18.78M derived: sum of 2 quarters · filed 2026-08-10 | -$27.40M derived: sum of 3 quarters · filed 2026-08-10 | -$35.10M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$8.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$17.36M derived: sum of 2 quarters · filed 2026-03-30 | -$25.06M derived: sum of 3 quarters · filed 2026-08-10 | -$32.77M 10-K · filed 2026-03-30 |
| 2025-09-30 | -$8.62M 10-Q · filed 2025-11-12 | -$16.32M derived: sum of 2 quarters · filed 2026-08-10 | -$24.03M 10-Q · filed 2025-11-12 | -$31.93M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | -$7.70M 10-Q · filed 2026-08-10 | -$15.41M 10-Q · filed 2026-08-10 | -$23.31M derived: sum of 3 quarters · filed 2026-08-10 | -$29.58M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$7.71M 10-Q · filed 2026-08-10 | -$15.61M derived: sum of 2 quarters · filed 2026-08-10 | -$21.88M derived: sum of 3 quarters · filed 2026-08-10 | -$27.00M derived: sum of 4 quarters · filed 2026-08-10 |
| 2024-12-31 | -$7.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$14.17M derived: sum of 2 quarters · filed 2026-03-30 | -$19.29M derived: sum of 3 quarters · filed 2026-03-30 | -$24.44M 10-K · filed 2026-03-30 |
| 2024-09-30 | -$6.27M 10-Q · filed 2025-11-12 | -$11.39M derived: sum of 2 quarters · filed 2025-11-12 | -$16.54M 10-Q · filed 2025-11-12 | -$21.70M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$5.12M 10-Q · filed 2025-11-12 | -$10.27M 10-Q · filed 2025-08-12 | -$15.43M derived: sum of 3 quarters · filed 2025-11-12 | -$19.90M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-03-31 | -$5.15M 10-Q · filed 2025-11-12 | -$10.31M derived: sum of 2 quarters · filed 2025-11-12 | -$14.78M derived: sum of 3 quarters · filed 2025-11-12 | -$19.26M derived: sum of 4 quarters · filed 2025-11-12 |
| 2023-12-31 | -$5.16M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | -$9.63M derived: sum of 2 quarters · filed 2025-03-17 | -$14.11M derived: sum of 3 quarters · filed 2025-03-17 | -$19.38M 10-K · filed 2025-03-17 |
| 2023-09-30 | -$4.47M 10-Q · filed 2024-11-13 | -$8.95M derived: sum of 2 quarters · filed 2024-11-13 | -$14.22M 10-Q · filed 2024-11-13 | -$17.97M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$4.48M 10-Q · filed 2024-11-13 | -$9.75M 10-Q · filed 2024-08-07 | -$13.50M derived: sum of 3 quarters · filed 2024-11-13 | -$16.56M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-03-31 | -$5.27M 10-Q · filed 2024-11-13 | -$9.02M derived: sum of 2 quarters · filed 2024-11-13 | -$12.08M derived: sum of 3 quarters · filed 2024-11-13 | -$15.44M derived: sum of 4 quarters · filed 2024-11-13 |
| 2022-12-31 | -$3.75M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | -$6.81M derived: sum of 2 quarters · filed 2024-03-19 | -$10.17M derived: sum of 3 quarters · filed 2024-03-19 | -$13.68M 10-K · filed 2024-03-19 |
| 2022-09-30 | -$3.06M 10-Q · filed 2023-11-13 | -$6.42M derived: sum of 2 quarters · filed 2023-11-13 | -$9.93M 10-Q · filed 2023-11-13 | -$13.17M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$3.36M 10-Q · filed 2023-11-13 | -$6.87M 10-Q · filed 2023-08-14 | -$10.11M derived: sum of 3 quarters · filed 2023-11-13 | -$13.56M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-03-31 | -$3.51M 10-Q · filed 2023-11-13 | -$6.75M derived: sum of 2 quarters · filed 2023-11-13 | -$10.20M derived: sum of 3 quarters · filed 2023-11-13 | -$13.48M derived: sum of 4 quarters · filed 2023-11-13 |
| 2021-12-31 | -$3.25M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | -$6.70M derived: sum of 2 quarters · filed 2023-03-28 | -$9.97M derived: sum of 3 quarters · filed 2023-03-28 | -$13.59M 10-K · filed 2023-03-28 |
| 2021-09-30 | -$3.45M 10-Q · filed 2022-11-09 | -$6.72M derived: sum of 2 quarters · filed 2022-11-09 | -$10.35M 10-Q · filed 2022-11-09 | -$14.55M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$3.27M 10-Q · filed 2022-11-09 | -$6.90M 10-Q · filed 2022-08-11 | -$11.10M derived: sum of 3 quarters · filed 2022-11-09 | -$14.29M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-03-31 | -$3.62M 10-Q · filed 2022-11-09 | -$7.82M derived: sum of 2 quarters · filed 2022-11-09 | -$11.02M derived: sum of 3 quarters · filed 2022-11-09 | -$13.49M derived: sum of 4 quarters · filed 2022-11-09 |
| 2020-12-31 | -$4.20M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | -$7.39M derived: sum of 2 quarters · filed 2022-03-14 | -$9.87M derived: sum of 3 quarters · filed 2022-03-14 | -$12.29M 10-K · filed 2022-03-14 |
| 2020-09-30 | -$3.19M 10-Q · filed 2021-11-10 | -$5.67M derived: sum of 2 quarters · filed 2021-11-10 | -$8.09M 10-Q · filed 2021-11-10 | -$10.57M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | -$2.47M 10-Q · filed 2021-11-10 | -$4.90M 10-Q · filed 2021-08-11 | -$7.38M derived: sum of 3 quarters · filed 2021-11-10 | -$9.83M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-03-31 | -$2.42M 10-Q · filed 2021-11-10 | -$4.91M derived: sum of 2 quarters · filed 2021-11-10 | -$7.35M derived: sum of 3 quarters · filed 2021-11-10 | -$9.82M derived: sum of 4 quarters · filed 2021-11-10 |
| 2019-12-31 | -$2.48M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-10 | -$4.93M derived: sum of 2 quarters · filed 2021-03-10 | -$7.40M derived: sum of 3 quarters · filed 2021-03-10 | -$10.65M 10-K · filed 2021-03-10 |
| 2019-09-30 | -$2.45M 10-Q · filed 2020-11-04 | -$4.92M derived: sum of 2 quarters · filed 2020-11-04 | -$8.17M 10-Q · filed 2020-11-04 | -$10.13M derived: sum of 4 quarters · filed 2020-11-04 |
| 2019-06-30 | -$2.47M 10-Q · filed 2020-11-04 | -$5.72M 10-Q · filed 2020-08-11 | -$7.68M derived: sum of 3 quarters · filed 2020-11-04 | -$9.07M derived: sum of 4 quarters · filed 2020-11-04 |
| 2019-03-31 | -$3.25M 10-Q · filed 2020-11-04 | -$5.21M derived: sum of 2 quarters · filed 2020-11-04 | -$6.60M derived: sum of 3 quarters · filed 2020-11-04 | -$8.34M derived: sum of 4 quarters · filed 2020-11-04 |
| 2018-12-31 | -$1.96M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-23 | -$3.35M derived: sum of 2 quarters · filed 2020-03-23 | -$5.08M derived: sum of 3 quarters · filed 2020-03-23 | -$5.73M 10-K · filed 2020-03-23 |
| 2018-09-30 | -$1.39M 10-Q · filed 2019-11-13 | -$3.12M derived: sum of 2 quarters · filed 2019-11-13 | -$3.77M 10-Q · filed 2019-11-13 | |
| 2018-06-30 | -$1.74M 10-Q · filed 2019-08-13 | -$2.38M 10-Q · filed 2019-08-13 | ||
| 2018-03-31 | -$650.00K 10-Q · filed 2019-05-13 | |||
| 2017-12-31 | -$4.26M 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |